Home » Newsletters » BioWorld Science

BioWorld Science

May 14, 2003

View Archived Issues

Microscience and Abgenix to develop monoclonal antibodies for infectious disease

SBIR grant to fund Avanir antibody development for cytomegalovirus

BioSante announces positive phase II/III results for Bio-E-Gel

Neurochem licenses preclinical diabetes technology to Innodia

Phase II testing commences for Glucoprime

Isis expands and advances development pipeline

Antisoma: Q1 developments

Migration inhibitory factor (MIF): a novel target for wound healing

Vanilloid receptor antagonism prevents DSS-induced colitis in rats

Genaera reports early findings for squalamine in AMD

Antiviral activity of new ribonucleoside analogue

Cheil Jedang claims two series of COX-2 inhibitors for use in gastrointestinal disorders

Novel PLA2 inhibitors with antiinflammatory and analgesic activity claimed by Nippon Soda

Melanocortin receptor modulators in early development at Neurocrine Biosciences

NeuroSearch describes AMPA receptor modulators, their preparation and biological activity

Recent Shionogi patent covers new DHODH inhibitors

Mitsubishi Pharma scientists prepare and test new chemokine receptor antagonists

Novel aldose reductase inhibitors covered by Otsuka patent

Takeda presents vanilloid agonists for urinary incontinence and pain

Raptiva rheumatoid arthritis trial discontinued

Epimmune and Anosys enter definitive merger agreement

Preliminary results from phase IIb trial of renzapride in c-IBS

FDA approves revised labeling for Flonase

Phase II study suggests pirfenidone may be more effective in IPF than prednisone

3M submits Aldara sNDA for actinic keratosis

IND submitted for Hynic-Annexin V

BioVex signs letter of intent with NIAID for development of HIV vaccine

HCT-1026 pharmacokinetic results in humans